The aim of the present study was to evaluate functional changes of mGluR5 expression in advanced Alzheimer's disease (AD) using positron emission tomography (PET) with an mGluR5 specific radiotracer ([18F]FPEB) in 5xFAD AD model. Subsequently, in the same animal, mGluR5 expression was quantified by immunoassay techniques. The non-displaceable binding potential values for mGluR5 was estimated by the Logan's graphical analysis. Brain PET imaging revealed that radioactivities in the hippocampus and the striatum were significantly lower in 5xFAD mice compared to control animals. Binding values were also significantly lowered in 5xFAD mice. This decline was validated by immunoblotting of protein isolates from brain tissues, as the mean band dens...
BackgroundPerturbed functional coupling between the metabotropic glutamate receptor-5 (mGluR5) and N...
Parkinson\u27s disease (PD) is a prevalent degenerative disorder affecting the CNS that is primarily...
The development of new diagnostic criteria for Alzheimer's disease (AD) requires new in vivo markers...
AbstractAlzheimer's disease (AD) is characterized by aggregation of amyloid beta (Aβ) into insoluble...
Magnetic resonance imaging (MRI) and positron emission tomography (PET) have made great strides in t...
Purpose. 18F-FC119S is a positron emission tomography (PET) tracer for imaging β-amyloid (Aβ) plaque...
Magnetic resonance imaging (MRI) and positron emission tomography (PET) have made great strides in t...
Metabotropic glutamate receptors (mGluRs) have become a pharmacological target for neuroprotective d...
Imaging of type 1 metabotropic glutamate receptor (mGluR1) has recently become possible using positr...
This work sought to characterize novel and existing radioligands, assessing their utility and effect...
Although the pathogenesis underlying behavioral variant frontotemporal dementia (bvFTD) has yet to b...
Metabotropic glutamate receptors play a critical role in the pathogenesis of Alzheimer's disease due...
In Alzheimer’s disease (AD), persistent microglial activation as sign of chronic neuroinflammation c...
Animal models of Alzheimer’s disease amyloidosis that recapitulate cerebral amyloid-beta pathology h...
Glutamate is the main excitatory neurotransmitter in the central nervous system, responsible for a p...
BackgroundPerturbed functional coupling between the metabotropic glutamate receptor-5 (mGluR5) and N...
Parkinson\u27s disease (PD) is a prevalent degenerative disorder affecting the CNS that is primarily...
The development of new diagnostic criteria for Alzheimer's disease (AD) requires new in vivo markers...
AbstractAlzheimer's disease (AD) is characterized by aggregation of amyloid beta (Aβ) into insoluble...
Magnetic resonance imaging (MRI) and positron emission tomography (PET) have made great strides in t...
Purpose. 18F-FC119S is a positron emission tomography (PET) tracer for imaging β-amyloid (Aβ) plaque...
Magnetic resonance imaging (MRI) and positron emission tomography (PET) have made great strides in t...
Metabotropic glutamate receptors (mGluRs) have become a pharmacological target for neuroprotective d...
Imaging of type 1 metabotropic glutamate receptor (mGluR1) has recently become possible using positr...
This work sought to characterize novel and existing radioligands, assessing their utility and effect...
Although the pathogenesis underlying behavioral variant frontotemporal dementia (bvFTD) has yet to b...
Metabotropic glutamate receptors play a critical role in the pathogenesis of Alzheimer's disease due...
In Alzheimer’s disease (AD), persistent microglial activation as sign of chronic neuroinflammation c...
Animal models of Alzheimer’s disease amyloidosis that recapitulate cerebral amyloid-beta pathology h...
Glutamate is the main excitatory neurotransmitter in the central nervous system, responsible for a p...
BackgroundPerturbed functional coupling between the metabotropic glutamate receptor-5 (mGluR5) and N...
Parkinson\u27s disease (PD) is a prevalent degenerative disorder affecting the CNS that is primarily...
The development of new diagnostic criteria for Alzheimer's disease (AD) requires new in vivo markers...